We performed a systematic review and meta-analysis to fully investigate the rash and pruritus of programmed death-1 (PD-1) inhibitors in cancer patients. The relevant studies of the randomized controlled trials in cancer patients treated with PD-1 inhibitors were retrieved, and a systematic evaluation was conducted. EMBASE, MEDLINE, and PubMed were searched for articles published up to April 2018. Nineteen randomized controlled trials and 11,006 patients were included. The current meta-analysis suggests that the use of PD-1 inhibitors significantly increases the risk of developing the all-grade rash (risk ratio [RR] 1.41; 95%CI 1.14-1.76; P = .002) and pruritus (RR 1.77; 95%CI 1.26-2.49; P = .001), and there was no difference between high-grade rash and pruritus. The RR of all-grade rash and pruritus did not vary significantly according to the type of drug, type of cancer, the line of therapy, or the treatment regimen. But both all-grade rash and pruritus varied significantly according to control therapy. The current metaanalysis suggests that the use of PD-1 inhibitors significantly increases the risk of developing all-grade rash and pruritus. Physicians should be aware of these adverse events and should monitor cancer patients who are receiving PD-1 inhibitors.
Antibodies that target key immune checkpoints, such as programmed death-1 (PD-1), have emerged as clinically effective treatment options for melanoma and other tumor types. The United States Food and Drug Administration's approval of nivolumab and pembrolizumab had brought hope to the patients and the scientific community. 1, 2 Nivolumab is an engineered humanized IgG4 anti-PD-1 antibody that has been approved for the management of unresectable or metastatic melanoma, metastatic squamous non-small-cell lung cancer (NSCLC), and advanced renal cell carcinoma. 3, 4 Pembrolizumab is another human PD-1-blocking antibody that has been approved for the management of NSCLC, melanoma, and squamous-cell carcinoma of the head and neck. 5, 6 Furthermore, the combination of anti-PD-1 antibodies and other drugs also showed significant effects in many refractory cancers.
Although anti-PD-1 immune checkpoint monoclonal antibodies are relatively well tolerated and used routinely alone or in combination with different chemotherapy regimens, they also cause a series of immune-related adverse events (irAEs). Dermatologic toxicities appear to be a kind of the most prevalent irAEs with PD-1 inhibitors. They occur in more than one-third of the patients treated with these monoclonal antibodies, regardless of the cancer being treated. 7, 8 As reported in clinical trials, the most frequently reported dermatologic toxicities associated with PD-1 inhibitors are rash and pruritus. Recognition and management of dermatologic toxicity are important issues in patients treated with PD-1 inhibitors because they may affect their quality of life (QOL) and lead to infection, pain, discomfort, and limitation of activities of daily living. However, the risk of rash and pruritus in cancer patients treated with PD-1 inhibitors varies widely across clinical trials, and risk factors underlying the variation are still unclear. Therefore, we conducted this metaanalysis of 19 randomized controlled trials (RCTs) to fully investigate these adverse events of PD-1 inhibitors in patients with cancer.
keywords: "nivolumab," "Opdivo," "pembrolizumab," "Keytruda" "tumor," and "cancer." The search was limited to RCTs published in English. We also performed independent searches using EMBASE between January 1, 1974, and April 30, 2018 to ensure that no clinical trials were overlooked. At each screening level, investigators of the review team selected articles for inclusion independently after an initial calibration exercise. RCTs that met the following criteria were included: (1) randomized controlled phase 2 and 3 trials in patients with cancer; (2) participants assigned to treatment with nivolumab or pembrolizumab; and (3) events or event rate and sample sizes available for rash and pruritus. PD-1 inhibitors in both treatment and control arms were excluded. The primary outcome measure was rash; the secondary outcome measure was pruritus.
Data Extraction
We extracted details on study characteristics, treatment information, results, and safety profiles from selected trials. Data were extracted by 1 investigator and checked by another investigator. If a particular patient population was reported in more than 1 publication with the same outcome parameters, the article providing the most detailed data was included in the metaanalysis. Rash and pruritus were defined per version 4.0 of the National Cancer Institute's CTCAE (Common Terminology Criteria for Adverse Events) criteria.
Quality Assessment
Each study was independently assessed for quality and for potential bias by 2 reviewers based on a randomization procedure; allocation concealment; blinding; study withdrawals; intention-to-treat analyses; and comparability between groups at baseline. Two reviewers independently assessed each study for quality and risk of bias using the Jadad ranking system. 10 Disagreements were resolved by consensus.
Data Analysis
Data were calculated by Review Manager Version 5.2. For the outcomes, the risk ratio (RR) was calculated for dichotomous data. We used the Mantel-Haenszel method to calculate 95%CI and RRs. The 95%CI was calculated for all types of data. Heterogeneity was quantified by calculating the I 2 statistic. An I 2 estimate >50% was regarded as indicating a high level of heterogeneity, and its causes were investigated. RRs were calculated using random-effects (I 2 > 50) or fixedeffects (I 2 < 50) models depending on the heterogeneity of included studies. Subgroup analysis was conducted to examine whether the RRs of rash and pruritus varied by the type of drug, line of therapy (first line vs ࣙ second line), type of cancer (NSCLC vs melanoma vs other tumor types), control therapy (placebo vs chemotherapy vs monoclonal antibodies), and treatment regimen (PD-1 inhibitor monotherapy vs combination therapy). The Mantel-Haenszel method was employed to assess significance in subgroup analyses. Trial-specific RRs of rash and pruritus were combined to compute summary estimates using a random-effects model, which considers both within-study and betweenstudy variation.
Results
The literature search yielded 575 potentially relevant trials. The initial screening excluded 510 trials for at least 1 of the following reasons: reviews, letters, nonrandomized trials, case reports, retrospective studies, meta-analysis, not human studies. The remaining 65 RCTs were carefully screened, and an additional 46 were excluded for not being phase 2 or phase 3 trials or other reasons. The remaining 19 trials were judged to be eligible for the present meta-analysis (14 phase 2 and 5 phase 3 trials, Figure 1 ).
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Characteristics of Included Studies A total of 11,006 patients were available for the metaanalysis. When examination was by agent, nivolumab was investigated in 12 trials and pembrolizumab in 7 trials. The most common underlying malignancies represented were NSCLC, squamous cellcarcinoma, melanoma, gastric cancer, and urothelial carcinoma. The methods of randomization were reported in all the included studies. Nine of these studies were open-label studies, and 10 were double-blind studies. Concealment was reported in 9 studies. Intention-to-treat webanalysis was conducted in 17 studies. All of these RCTs were judged to be of good quality (Jadad score ࣙ 4/5). The characteristics of the included trials are summarized in Table 1 .
Risk Ratio of Rash
All-grade rash occurred in 971 of 5956 patients in the PD-1 inhibitors arms and in 689 of 5206 in the control arms. The RR of all-grade rash was 1.41 (95%CI 1.14-1.76; P = .002, Figure 2A ). High-grade (ࣙ grade 3) rash occurred in 48 of 4508 patients in the PD-1 inhibitors arms and in 24 of 3986 in the control arms. The RR of high-grade rash was 1.52 (95%CI 0.96-2.40; P = .07, Figure 2B ). Thus, patients treated with these agents had a significantly increased risk of all-grade rash, and there was no significant difference of high-grade rash. Significant heterogeneity was detected among the studies of all-grade rash (P < .00001, I 2 = 79%), which might be due to the different drug types, tumor types, control groups, or line of therapy. Therefore, subgroup analyses were performed according to these differences. In order to explore the impact of individual agents on the RRs of all-grade rash, we calculated RRs according to the type of agent used. There were no significant differences in the RRs by type of drug (P = .21). We further analyzed the RRs of all-grade rash in patients with different cancer types, and we found no significant differences in the RRs by type of cancer (P = .26). Studies were further stratified according to control therapy, and significant differences in the RRs were found for all-grade rash (P = .0001). There is a statistically significant difference in skin rash for both PD-1 inhibitor versus other monoclonal antibodies and for PD-1 inhibitor versus chemotherapy (P < .0001). We found that there was no difference in the risk of all-grade rash between PD-1 inhibitors and other monoclonal antibodies (P = .09). However, patients treated with PD-1 inhibitors had a significantly increased risk of all-grade rash when compared with chemotherapy (P < .0001) or placebo (P < .0001).
Studies were further stratified according to treatment regimen (PD-1 inhibitor monotherapy vs combination treatment) and treatment line (first line vs ࣙ second line). There was no significant difference in the RRs by treatment regimen (P = .50) and treatment line (P = .68) for all-grade rash ( Table 2 ).
Risk Ratio of Pruritus
All-grade pruritus occurred in 1022 of 5005 patients in the PD-1 inhibitors arms and in 722 of 4351 in the control arms. The RR of all-grade pruritus was 1.77 (95%CI 1.26-2.49; P = .001, Figure 3A ). High-grade (ࣙ grade 3) pruritus occurred in 13 of 2285 patients in the PD-1 inhibitors arms, and 8 of 2162 in the control arms. The RR of high-grade pruritus was 1.31 (95%CI 0.60-2.84; P = .49, Figure 3B ). Therefore, patients treated with PD-1 inhibitors had a significant increased risk of all-grade pruritus, whereas there was no significant difference for high-grade pruritus. Significant heterogeneity was detected among the studies of allgrade pruritus (P < .00001, I 2 = 91%), which might be due to the different drug types, tumor types, control groups, or line of therapy. Therefore, subgroup analyses were performed according to these differences.
In the subgroup analysis, we calculated RRs according to the type of agent used. We found there were no significant differences in the RRs by type of drug (P = .20).
We further analyzed the RRs of all-grade rash in patients with different cancer types, and found no significant difference in the RRs by type of drug (P = .39). Studies were further stratified according to control therapy, and there was a significant difference in the RRs for all-grade pruritus (P < .00001). There is a statistically significant difference in skin pruritus for both PD-1 inhibitor versus other monoclonal antibodies and PD-1 inhibitor versus chemotherapy (P < .00001). We found that there was no difference in the risk of all-grade pruritus between PD-1 inhibitors and other monoclonal antibodies (P = .16). However, patients treated with PD-1 inhibitors had a significantly increased risk of all-grade pruritus when compared with chemotherapy (P < .00001) or placebo (P = .0002). Studies were further stratified according to treatment regimen (PD-1 inhibitor monotherapy vs combination treatment) and treatment line (first line vs ࣙ second line). There was no significant difference in the RRs by treatment regimen (P = .68) or treatment line (P = .97) for all-grade pruritus (Table 3) .
Publication Bias
Funnel plots of the studies used in the meta-analysis to evaluate all-grade and high-grade rash are shown in Figure 4 ( Figure 4A , all-grade rash; Figure 4B , high-grade rash). No significant publication bias was found in the analysis.
Discussion
The development of immune checkpoint inhibitors represents a major breakthrough in cancer therapy. Due to their unique mechanism of action, however, immune checkpoint inhibitors have a very specific safety profile. They entail a new spectrum of irAEs that are mostly of a mechanism-based immune nature, mediated by the triggering of cytotoxic CD4+/CD8+ T-cell activation. Dermatologic toxicities appear to be the most prevalent irAEs with anti-PD-1. The pathophysiologic mechanisms governing cutaneous irAEs have not been reported. However, they are clearly related to T-cell activation mediated by blockade of PD-1 receptors. The aberrant targeting of dermal-epidermal antigens by reactivated CD4+/CD8+ T cells still needs to be identified. 30 As reported in clinical trials, the most frequently reported dermatologic toxicities associated with PD-1 inhibitors are rash and pruritus.
The development of these toxicities may lead to anticancer therapy dose modifications and/or termination, in addition to impairing patients' health-related QOL. Therefore, we performed this meta-analysis to fully investigate the rash and pruritus of PD-1 inhibitors in cancer patients.
Our meta-analysis revealed that use of PD-1 inhibitors was associated with a significantly increased risk of all-grade rash and pruritus. All-grade rash and pruritus were 1.41 and 1.77 times more likely to occur in patients receiving PD-1 inhibitors versus control groups, respectively. There was no difference of highgrade rash and pruritus between PD-1 inhibitors and controls.
To identify potential risk factors for all-grade rash and pruritus, we performed subgroup analysis according to the type of drug, type of cancer, line of therapy, control therapy, and treatment regimen. Our subgroup analysis suggested that the RR of all-grade rash and pruritus did not vary significantly according to the type of drug, type of cancer, the line of therapy, and treatment regimen. However, both of all-grade rash and pruritus varied significantly according to control therapy. It is noteworthy that PD-1 inhibitors tended to be associated with more all-grade rash and pruritus when compared to placebo and chemotherapy, but there was no significant difference when compared to other monoclonal antibodies such as ipilimumab. This might attributed to the fact that other kinds of monoclonal antibodies may also cause irAEs, which may result in increased risk of dermatologic toxicities such as rash and pruritus in those receiving these agents. Additionally, the different control groups might be a source of heterogeneity.
Some newly reported studies imply that there may be associations with some dermatologic adverse events (AEs) and positive outcomes. Researchers found that for patients treated with nivolumab, both rash and vitiligo were associated with prolonged progression-free survival and overall survival. 30 For pembrolizumab, patients who developed dermatologic AEs had longer progression-free intervals than those who did not. 31 Therefore, the development of these AEs may serve as a surrogate marker for treatment response.
Because the reason for this association is not yet well understood, further research is required to explain it. Skin-related irAEs are among the major toxicities caused by PD-1 inhibitors, with rash and pruritus being the most commonly observed. They are generally mild, but severe cases have been also reported. Therefore, with the increasing use of PD-1 inhibitors, recognition and management of irAEs will become more important for restricting dose-limiting toxicities and preventing a deleterious impact on a patient's health-related QOL. Immune checkpoint inhibitors can be maintained in the vast majority of cases, and treatment withholding is only rarely needed. Grades 1 and 2 skin rash and pruritis are considered acceptable, whereas grades 3 and 4 are considered intolerable. 32 For the management of grades 1 and 2 skin rash and pruritis, topical moisturizers applied to the full body surface, moderate-or highpotency topical steroids applied on affected areas, and oral antihistamines were usually adopted. For the severe reactions, topical moisturizers (if tolerated), highor very high-potency topical steroids (eg, clobetasol), oral antihistamines, or oral steroids (1 mg/[kg·day]) were usually adopted. For life-threatening reactions, permanent drug discontinuation and supportive measures were recommended. Early recognition, diagnosis, and appropriate therapy were required for maintaining dose intensity and mitigating the severity of cutaneous adverse events. 33 For the management of rash, systemic antihistamines and topical steroids are frequently used. The use of systemic corticosteroids is restricted to the management of persistent and severe reactions. Also, it is important to educate patients about cleansing, moisturization, and sun protection to prevent severe rash. [34] [35] [36] Pruritus also develops rapidly after the start of immunotherapy, either alone or in association with a skin rash. 37 There are no evidence-based guidelines on how to prevent or treat PD-1 inhibitor-induced pruritus. Supportive management should be advised, including oral antihistamines, topical steroids, and/or moisturizers.
A previous meta-analysis 32 evaluated the risk of dermatologic AEs observed with the use of pembrolizumab and nivolumab in cancer patients. The researchers found that pembrolizumab and nivolumab are both associated with dermatologic AEs such as rash and pruritus. However, only 4 RCTs were included in the meta-analysis, and all of the 4 RCTs were conducted in 2015. With the completion and publication of the huge number of PD-1 inhibitor studies in the past 3 years, we performed this up-to-date meta-analysis to fully investigate the rash and pruritus. In the present meta-analysis, 19 randomized controlled phase 2 and phase 3 trials were included, and all the RCTs were conducted from 2015 to 2018. To the best of our knowledge, this is the largest and most comprehensive meta-analysis evaluating the risk of rash and pruritus associated with PD-1 inhibitors.
Our study has some limitations. First, studies included in this meta-analysis were conducted at various international institutions by different investigators, and they may have potential bias in reported incidences of dermatologic AEs. Moreover, dermatologic AEs were not the primary end point of any included studies, which could result in a bias of reported incidence rates. Second, significant heterogeneity was detected among the trials of all-grade rash and pruritus. We tried to overcome this heterogeneity by using subgroup analyses, and we found that the different control therapies might be the primary source of heterogeneity. Moreover, different doses and frequencies of PD-1 inhibitor administration were used in the clinical trials, and the baseline characteristics of the patients were also different, which may increase the clinical heterogeneity of the trial. Third, data were abstracted from published clinical trial results, and individual patient information was not available. Thus, the analysis of the factors that potentially contributed to the development of dermatologic AEs, such as prior exposure to dermatologic AEs agents or prior radiation therapy, was not possible in this study.
Conclusions
In summary, this study has demonstrated that PD-1 inhibitors were associated with a significant increased risk of all-grade rash and pruritus, and there was no difference between high-grade rash and pruritus. The RR of all-grade rash and pruritus did not vary significantly according to the type of drug, type of cancer, the line of therapy, and treatment regimen. However, both allgrade rash and pruritus varied significantly according to control therapy. This meta-analysis adds some useful information on a relevant side-effect profile, and timely recognition of these toxicities can help with proper management of patients undergoing treatment with PD-1 inhibitors.
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